KPV (Alpha-MSH Fragment) vs TB-500
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
A powerful fragment of thymosin beta-4 that acts like your body's repair signal—speeding up healing of muscles, tendons, and tissues by promoting cell migration and new blood vessel growth right where you need it most.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
KPV (Alpha-MSH Fragment)
300–500 mcg
TB-500
2–2.5 mg
Frequency
KPV (Alpha-MSH Fragment)
Once daily
TB-500
Twice weekly
Administration
KPV (Alpha-MSH Fragment)
Oral
TB-500
Subcutaneous injection
Cycle length
KPV (Alpha-MSH Fragment)
Ongoing/indefinite
TB-500
4-6 weeks
Onset speed
KPV (Alpha-MSH Fragment)
Moderate (1-2 weeks)
TB-500
Moderate (1-2 weeks)
Evidence level
KPV (Alpha-MSH Fragment)
Strong human trials (Phase 3 or FDA approved)
TB-500
Moderate human trials (Phase 1-2)
Benefit ratings
Anti-Inflammatory
Gut Health
Healing & Recovery
Healing Speed
Tissue Repair
Anti-Scarring
Compound specifications
KPV (Alpha-MSH Fragment)
Molecular formula
C16H30N4O4
Molecular weight
342.43 Da
Half-life
Short peptide half-life; improved by nanoparticle and hydrogel formulations
Bioavailability
Oral uptake via PepT1 transporter; enhanced by nanoparticle formulations
CAS number
67727-97-3
TB-500
Molecular formula
C38H68N10O14
Molecular weight
889.01 g/mol
Half-life
2-3 days (systemic)
Bioavailability
High via subcutaneous injection (~100%)
CAS number
885340-08-9
Dosing compared
KPV (Alpha-MSH Fragment)
Subcutaneous
200 mcg
Once daily · 4-6 weeks
Lower end of the subcutaneous practice range for systemic anti-inflammatory use; KPV is the C-terminal tripeptide of alpha-MSH and acts on NF-kB signaling [3][6].
300-500 mcg
Once daily · 4-6 weeks
Most commonly used subcutaneous practice dose for systemic/extra-intestinal inflammation; some practitioners escalate toward 500 mcg during acute flares [6].
Oral
1000-1500 mcg
Once daily · 4-6 weeks
Oral route is used for gut-directed effects (e.g., IBD/ulcerative colitis models), taking advantage of PepT1 uptake; preclinical colitis studies support this application, doses are research practice [2][6].
Topical
0.01-0.1% cream or serum
Twice daily · 7-14 days (acute) up to 4-8 weeks (chronic)
Applied as a 0.01-0.1% topical formulation to affected skin for localized inflammation (eczema, rosacea, post-procedure redness); penetration enhancers are often added. Research/practice use [6].
TB-500
Subcutaneous
2-2.5 mg
Twice weekly · Loading phase, 4-6 weeks
Research peptide with no human trials of the fragment; [9] loading doses used in practice [6].
2-2.5 mg
Once weekly · Maintenance after loading
Maintenance dose used in practice following the loading phase [6].
Best suited for
KPV (Alpha-MSH Fragment)
Inflammatory bowel disease research
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gut anti-inflammatory therapy development
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Skin inflammation and wound healing
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated inflammation studies
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
TB-500
Athletes Recovering from Muscle Injuries
If you've pulled a hamstring, strained your back, or torn a muscle, TB-500 helps accelerate the healing process by promoting cell migration to the injury site and supporting new blood vessel growth. It's especially useful for injuries that just won't seem to fully heal [1][5].
Tendon and Ligament Problems
Tendons and ligaments are notoriously slow healers because they have poor blood supply. TB-500 promotes angiogenesis (new blood vessel formation) and helps repair these stubborn connective tissue injuries—think Achilles tendonitis, tennis elbow, or rotator cuff issues [5].
Post-Surgical Recovery
After surgery, your body needs to repair a lot of tissue quickly. TB-500 supports wound healing, reduces inflammation, and may help minimize scar tissue formation. Some protocols use it alongside traditional recovery to potentially speed up the healing timeline [1][4].
Chronic Inflammation and Slow Healers
Some people just heal slowly—whether due to age, diabetes, or other factors. TB-500 helps regulate the inflammatory response and promotes the cellular processes needed for tissue repair. It essentially tells your body to focus healing resources where they're needed most [1].
Side effects
KPV (Alpha-MSH Fragment)
Common
- Injection Site Reaction
- Mild GI Effects
- Transient Skin Effects
- Mild Immune Modulation
- Peptide Stability Concerns
Uncommon
- Theoretical Immunosuppression
Serious
- Immune Tolerance Development
TB-500
Common
- Injection site redness
- Mild fatigue or lethargy
- Mild headache
- Slight flushing
Uncommon
- Head rush or lightheadedness
- Temporary nausea
Serious
- Allergic reaction
Safety & evidence
KPV (Alpha-MSH Fragment)
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
Contraindications
- Not approved for human clinical use
- Unknown interactions with immunosuppressive medications
- Insufficient safety data for pregnancy and lactation
- Potential melanocortin receptor effects in susceptible individuals
TB-500
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
TB-500 has shown a good safety profile across preclinical studies and limited human research. It's a fragment of thymosin beta-4, a naturally occurring protein in your body involved in healing. Most side effects are mild and transient, primarily injection site reactions. However, large-scale clinical trials are still needed to fully establish its safety profile in humans [1].
Contraindications
- Pregnancy or planning to become pregnant
- Currently breastfeeding
- Active cancer or history of cancer
- Known allergy to peptide components
- Children and adolescents
Which is right for you?
Choose KPV (Alpha-MSH Fragment) if...
- Inflammatory bowel disease research
- Gut anti-inflammatory therapy development
- Skin inflammation and wound healing
- Cytokine-mediated inflammation studies
Choose TB-500 if...
- Accelerating injury recovery
- Tendon and ligament healing
- Reducing chronic inflammation
- Post-surgical recovery support